Kent J. Weinhold

发表

Induction of Plasma (TRAIL), TNFR-2, Fas Ligand, and Plasma Microparticles after Human Immunodeficiency Virus Type 1 (HIV-1) Transmission: Implications for HIV-1 Vaccine Design

B. Haynes, S. Self, G. Shaw, 2008, Journal of Virology.

CD8 CTL responses in vaccines: emerging patterns of HLA restriction and epitope recognition.

M. McElrath, P. Goepfert, G. Ferrari, 2001, Immunology letters.

Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein.

M. McElrath, P. Goepfert, Yuwei Zhu, 2004, The Journal of infectious diseases.

Identification of highly conserved and broadly cross-reactive HIV type 1 cytotoxic T lymphocyte epitopes as candidate immunogens for inclusion in Mycobacterium bovis BCG-vectored HIV vaccines.

S. Osmanov, G. Ferrari, K. Weinhold, 2000, AIDS research and human retroviruses.

Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group.

R. Siliciano, E. Paoletti, J. Mascola, 1998, The Journal of infectious diseases.

Priming of anti-human immunodeficiency virus (HIV) CD8+ cytotoxic T cells in vivo by carrier-free HIV synthetic peptides.

B. Haynes, R. Scearce, K. Weinhold, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Induction of Plasma (TRAIL), TNFR-2, Fas Ligand, and Plasma Microparticles after Human Immunodeficiency Virus Type 1 (HIV-1) Transmission: Implications for HIV-1 Vaccine Design

D. Pisetsky, L. Qin, J. Whitesides, 2008, Journal of Virology.

Coadministration of zidovudine and interleukin-2 increases absolute CD4 cells in subjects with Walter Reed stage 2 human immunodeficiency virus infection: results of ACTG protocol 042.

J. Bartlett, G. Petroni, K. Weinhold, 1998, The Journal of infectious diseases.

Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network.

R. Belshe, B. Graham, R. Sposto, 1994, JAMA.

Herpesvirus saimiri transformation of HIV type 1 suppressive CD8+ lymphocytes from an HIV type 1-infected asymptomatic individual.

C. McDanal, M. Greenberg, S. Lacey, 1998, AIDS research and human retroviruses.

CD8+ T cell-mediated suppressive activity inhibits HIV-1 after virus entry with kinetics indicating effects on virus gene expression.

G. Ferrari, C. McDanal, K. Weinhold, 2000, Proceedings of the National Academy of Sciences of the United States of America.

A distinctive clade B HIV type 1 is heterosexually transmitted in Trinidad and Tobago.

W. Blattner, T. O'Brien, J. Carr, 2000, Proceedings of the National Academy of Sciences of the United States of America.

3'-Azido-3'-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase

K. Weinhold, C. Richards, T. Spector, 1987, Antimicrobial Agents and Chemotherapy.

Conversion of an immunogenic human immunodeficiency virus (HIV) envelope synthetic peptide to a tolerogen in chimpanzees by the fusogenic domain of HIV gp41 envelope protein

B. Haynes, L. Arthur, R. Scearce, 1993, The Journal of experimental medicine.

Alterations in antibody-dependent cellular cytotoxicity during the course of HIV-1 infection. Humoral and cellular defects.

J. Bartlett, D. Tyler, H. Lyerly, 1990, Journal of immunology.

Characterization of CD4 and CD8 T cell responses in MuSK myasthenia gravis.

D. Sanders, K. Weinhold, J. Massey, 2014, Journal of autoimmunity.

CD8+ T lymphocyte-mediated inhibition of HIV-1 long terminal repeat transcription: a novel antiviral mechanism.

J. Bartlett, D. Bolognesi, M. Greenberg, 1993, AIDS research and human retroviruses.

Immunization with Cocktail of HIV-Derived Peptides in Montanide ISA-51 Is Immunogenic, but Causes Sterile Abscesses and Unacceptable Reactogenicity

B. Haynes, D. Montefiori, D. Stablein, 2010, PloS one.

Preparation and characterization of an intravenous solution of IgG from human immunodeficiency virus-seropositive donors.

T. Matthews, K. Weinhold, C. Perno, 1991, Blood.

HIV-1 neutralizing monoclonal antibodies induced by a synthetic peptide.

L. Bacheler, M. Rayner, R. Pomerantz, 1990, AIDS research and human retroviruses.

HIV-1 GP120-mediated immune suppression and lymphocyte destruction in the absence of viral infection.

H. Lyerly, D. Bolognesi, T. Matthews, 1989, Journal of immunology.

Identification of sites within gp41 that serve as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodies.

S. Zolla-Pazner, M. Gorny, D. Tyler, 1990, Journal of immunology.

Lack of infection in HIV-exposed individuals is associated with a strong CD8(+) cell noncytotoxic anti-HIV response.

J. Skurnick, J. Sninsky, J. Levy, 1999, Proceedings of the National Academy of Sciences of the United States of America.

Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene.

R. Siliciano, E. Paoletti, J. Tartaglia, 1995, The Journal of infectious diseases.